When was Encellin founded?

Encellin was founded in 2015 and raised its 1st funding round 4 years after it was founded.

Where is Encellin located?

Encellin is headquartered in San Francisco, United States.

Who is the current CEO of Encellin?

Crystal Nyitray of Encellin. They have also founded 1 company.

How many employees does Encellin have?

As of Jun 30, 2026, the latest employee count at Encellin is 8.

Is Encellin a funded company?

Encellin is a funded company, having raised a total of $18.1M across 4 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jul 19, 2019.

When was the latest funding round of Encellin?

Encellin's latest funding was a $***** Series A round on Sep 20, 2023, with participation from 2 investors. Its primary sector is Wound Care. In United States, the Wound Care sector has seen $52.4M in funding in 2026 to date.

Where does Encellin rank among its competitors?

Encellin ranks 13th amongst 69 active competitors, of which 23 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Conexeu Sciences, which secured $86.3K in Jun, 2026.

Who are the top competitors of Encellin?

Encellin's top competitors include Organogenesis, Acera Surgical and GeniPhys. Among them, Conexeu Sciences secured the most recent funding round in June, 2026.

Encellin - 2026 Company Profile, Team, Funding & Competitors

Company Details

Encellin is developing regenerative materials using cell transplant therapy. The company has developed cell transplant therapy for treating missing, damaged, or diseased cells and treatment of chronic diseases.

Website: www.encellin.com/
Social

Key Metrics

Founded Year

2015

Location

San Francisco, United States

Stage

Series A

Total Funding

$18.1M in 4 rounds

Latest Funding Round

Series A, Sep 20, 2023, $*****

Investors

Khosla Ventures & 9 more

Ranked

13^th among 69 active competitors

Employee Count

8 as on Jun 30, 2026

Similar Companies

Organogenesis & 77 more

View Encellin's full profile

Encellin has raised a total funding of $18.1M over 4 rounds. Its first funding round was on Jul 19, 2019. Its latest funding round was a Series A round on Sep 20, 2023 for $*****. 2 investors participated in its latest round. Encellin has 10 institutional investors.

Here is the list of recent funding rounds of Encellin:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 20, 2023	9716979	Series A	8955272	3330437	2202852	9277093
Aug 05, 2021	8658768	Seed	1324710	8801562	8813020	Sand Hill Angels & 1 more
Aug 20, 2019	7209620	Seed	3385536	8106454	Y Combinator	4874571

Access funding benchmarks and valuations. Sign up today!

View details of Encellin's funding rounds and investors

The founders of Encellin is Crystal Nyitray. Crystal Nyitray is the CEO of Encellin.

Here are the details of Encellin's key team members:

Crystal Nyitray: Founder & CEO of Encellin.
Contact Info: 1 email address

View details of Encellin's Founder profiles and Board Members

Encellin's employee count trend

Encellin has 8 employees as of Jun 26. Here is Encellin's employee count trend over the years:

Uncover Encellin's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Encellin include Organogenesis, Acera Surgical and GeniPhys. Here is the list of Top 10 competitors of Encellin, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Organogenesis 1985, Canton (United States), Public	Regenerative tissue innovations for advanced wound care and surgical solutions	$30M	Eastward Capital Partners, Spring St. Group ... & 2 others	59/100
2nd	Acera Surgical 2013, St. Louis (United States), Acquired	Provider of synthetic electrospun scaffolds for regenerative medical applications	$6.32M	St. Louis Arch Angels, Missouri Technology ... & 1 others	57/100
3rd	GeniPhys 2014, Zionsville (United States), Series A	Developer of collagen polymers for tissue regeneration	$13.5M	Elevate Ventures, America’s Seed Fund & 3 others	53/100
4th	BioTissue 2001, Miami (United States), Series C	Developer of regenerative biologic therapies for eye care	$110M	Ballast Point Ventures, RC Capital & 2 others	52/100
5th	Conexeu Sciences 2023, Vancouver (Canada), Public	Developer of products for skin restoration and wound care	$6.96M	-	46/100
6th	RenovoDerm 2016, Columbus (United States), Seed	Developer of nanofiber-based wound care devices	$775K	Proton Enterprises, Monte Carlo Capital & 1 others	46/100
7th	BioLab Sciences 2018, Scottsdale (United States), Unfunded	Developer of regenerative therapies for wound healing	-	-	44/100
8th	Reapplix 2008, Rudersdal (Denmark), Series B	Developer of patch system for wound healing	$52.4M	Seed Capital, Novo Holdings & 8 others	44/100
9th	Polaroid Therapeutics 2022, Schlieren (Switzerland), Unfunded	Developer of antimicrobial solutions for wound healing	-	-	44/100
10th	CLYRA Medical Technologies 2012, Westminster (United States), Seed	Developer of a regenerative technology for wound care	$50K	-	44/100
13th	Encellin 2015, San Francisco (United States), Series A	Developer of regenerative materials	$18.1M	Evolution VC Partners, SV Latam Capital & 8 others	40/100